# Egg-passaging mutations in influenza H3N2

Lab Meeting Katie Kistler February 20, 2018

production

Background: influenza vaccine

#### Influenza vaccine

• Seasonal flu burden: millions of cases, hundreds of thousands of deaths

Prevention via vaccine


Vaccine continually updated to combat antigenic drift

#### Influenza vaccine production

Hundreds of millions of doses yearly

- Mass-produced in embryonated chicken eggs
  - a. Make candidate vaccine virus (CVV)
  - b. Manufacturing facilities grow CVVs
  - c. Purification and inactivation of virus

#### Egg-adapted mutations during vaccine production



## Low vaccine effectiveness may be attributed to egg-adapted mutations

#### 2012-2013:

- 30-40% H3N2 vaccine effectiveness
- HA H156Q, G186V, S219Y


## Low vaccine effectiveness may be attributed to egg-adapted mutations

#### 2012-2013:

- 30-40% H3N2 vaccine effectiveness
- HA H156Q, G186V, S219Y

#### 2016-2017:

- 30-40% H3N2 vaccine effectiveness
- HA T160K reversion




## Low vaccine effectiveness may be attributed to egg-adapted mutations

#### 2012-2013:

- 30-40% H3N2 vaccine effectiveness
- HA H156Q, G186V, S219Y

#### 2016-2017:

- 30-40% H3N2 vaccine effectiveness
- HA T160K reversion



recombinant T160

egg-adapted K160

(Zost et al, 2017)

#### How to avoid egg-adapted mutations?

1. Egg-free vaccine production

2. Choose vaccine strains that will not mutate

# and their effect on vaccine effectiveness

Predict egg-adapted mutations

#### Published reports of egg mutations & their effects

## Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains

Seth J. Zost<sup>a</sup>, Kaela Parkhouse<sup>a</sup>, Megan E. Gumina<sup>a</sup>, Kangchon Kim<sup>b</sup>, Sebastian Diaz Perez<sup>a</sup>, Patrick C. Wilson<sup>c</sup>, John J. Treanor<sup>d</sup>. Andrea J. Sant<sup>e</sup>. Sarah Cobey<sup>b</sup>. and Scott E. Hensley<sup>a.1</sup>

of studies to determine whether the difference in glycosylation of HA antigenic site B of H3N2 vaccine strains and circulating strains contributed to a previously unrecognized vaccine mismatch during the 2016–2017 influenza season.

Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs

Bin Lu\*, Helen Zhou, Winnie Chan, George Kemble, Hong Jin

Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses

Lauren Parker, <sup>1,2</sup> Stephen A. Wharton, <sup>1,2</sup> Stephen R. Martin, <sup>1,3</sup> Karen Cross, <sup>1,2</sup> Yipu Lin, <sup>1,2</sup> Yan Liu, <sup>4</sup> Ten Feizi, <sup>4</sup> Rodney S. Daniels <sup>1,2</sup> and John W. McCauley <sup>1,2</sup> acterise the correlation between receptor-binding and the antigenic properties of these viruses. Using the vaccine virus Vic361e, recommended for use in vaccines in 2012 and 2013, as a prototype, a panel of viruses was generated by

Low 2012-13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses

Danuta M. Skowronski<sup>1,2</sup>\*, Naveed Z. Janjua<sup>2,3</sup>, Gaston De Serres<sup>4,5</sup>, Suzana Sabaiduc<sup>1</sup>, Alireza Eshaghi<sup>6</sup>, James A. Dickinson<sup>7</sup>, Kevin Fonseca<sup>5,9</sup>, Anne-Luise Winter<sup>10</sup>, Jonathan B. Gubbay<sup>11,12,13</sup>, Mel Krajden<sup>1,3</sup>, Martin Petric<sup>1,3</sup>, Hugues Charest<sup>14,15</sup>, Nathalie Bastien<sup>16</sup>, Trijntje L. Kwindt<sup>2</sup>, Salaheddin M. Mahmud<sup>17</sup>, Paul Van Caeseele<sup>18,19</sup>, Yan Li<sup>16,19</sup>

Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012–2013

Sarah Cobey, Sigrid Gouma, \* Kaela Parkhouse. \*2 Benjamin S. Chambers. \*2 Hildegund C. Ertl, \*3 Kenneth E. Schmader, \*3 Rebecca A. Halpin, \*4 Xudong Lin, \*1 Timothy B. Stockwell, \*5 Suman R. Das, \*6 Emily Landon, \*5 Vera Tesic. \*5 Ilan Youngster, \*7 Benjamin A. Pinsky, \*5 David E. Wentworth, \*6 Scott E. Hensley. \*6 and Yonatan H. Grad<sup>11,12</sup>

#### Immunodominance of Antigenic Site B over Site A of Hemagglutinin of Recent H3N2 Influenza Viruses

Lyubov Popova<sup>1,2</sup>, Kenneth Smith<sup>3</sup>, Ann H. West<sup>2</sup>, Patrick C. Wilson<sup>3,4,5</sup>, Judith A. James<sup>3</sup>, Linda F. Thompson<sup>4</sup>, Gillian M. Air<sup>1</sup>\*


recent H3 HAs. We mapped the binding of two human monoclonal antibodies to wild type A/Oklahoma/309 HA and mutant HAs derived from it, and we tested the reactivity of polyclonal antibodies in human plasma samples after seasonal vaccination in 2006 (H3N2 2006–07 component A/Wisconsin/67/05) and/or after vaccination in 2008 (H3N2 2008–09 component A/Uruguay/716/2007), to wild type HA and mutants in antigenic sites A and B. Our results indicate that most


# Predict egg-adapted mutations and their effect on vaccine effectiveness


**Existing literature-** individual studies on specific egg-adapted mutations in specific strains


My goal- use a phylogeny to identify:


- Common egg-adapted mutations
- Background specificity
- Epistasis between egg-adapted mutations
- Antigenic effect of egg-adapted mutations (titers model)















#### Common egg-passaging HA mutations


- HA1 L194P
- HA1 G186V
- HA1 T160K
- HA1 T203I
- HA1 S219F

- HA1 D225G
- HA1 S219Y
- HA1 A138S
- HA1 H156Q
- HA1 H156R


#### Mutations are egg-passaging-specific




#### Mutations are egg-passaging-specific




Background specificity of mutations





#### Background specificity of egg mutations


Genotype of virus influences whether it will mutate at that position during egg-passaging



#### Background specificity of egg mutations


Genotype of virus influences whether it will mutate at that position during egg-passaging

In the works: does HA genotype (proxy: clade) of virus determine whether it mutate during egg-passaging?




Epistasis between mutations


L194P OR G186V



L194P OR G186V



L194P OR G186V




### Pairwise epistatic interactions

$$\frac{observed}{expected} = \log_2 \frac{f_{194P\&186V}}{f_{194P} * f_{186V}}$$


#### Pairwise epistatic interactions

Epistasis between HA sites in egg-passaged influenza H3N2




$$\frac{observed}{expected} = \log_2 \frac{f_{194P\&186V}}{f_{194P} * f_{186V}}$$


1. Virus only mutates at other sites during egg-passaging if 160K (pos. epistasis)




- 1. Virus only mutates at other sites during egg-passaging if 160K (pos. epistasis)
- 2. Mutations at positions 186 and 194 are mutually exclusive (neg. epistasis)




- 1. Virus only mutates at other sites during egg-passaging if 160K (pos. epistasis)
- 2. Mutations at positions 186 and 194 are mutually exclusive (neg. epistasis)
- 3. Positions 219 and 156 do not mutate if 194 is mutated (neg. epistasis)




- 1. Virus only mutates at other sites during egg-passaging if 160K (pos. epistasis)
- 2. Mutations at positions 186 and 194 are mutually exclusive (neg. epistasis)
- 3. Positions 219 and 156 do not mutate if 194 is mutated (neg. epistasis)
- 4. Positions 138 and 203 do not mutate if 186 is mutated (neg. epistasis)



- 1. Virus only mutates at other sites during egg-passaging if 160K (pos. epistasis)
- 2. Mutations at positions 186 and 194 are mutually exclusive (neg. epistasis)
- 3. Positions 219 and 156 do not mutate if 194 is mutated (neg. epistasis)
- 4. Positions 138 and 203 do not mutate if 186 is mutated (neg. epistasis)
- 5. Mutation at 225 does not depend on 186 or 194



- 1. Virus only mutates at other sites during egg-passaging if 160K (pos. epistasis)
- 2. Mutations at positions 186 and 194 are mutually exclusive (neg. epistasis)
- 3. Positions 219 and 156 do not mutate if 194 is mutated (neg. epistasis)
- 4. Positions 138 and 203 do not mutate if 186 is mutated (neg. epistasis)
- 5. Mutation at 225 does not depend on 186 or 194



## Temporal order?

And temporal order

#### Background specificity + epistatic effects

How are mutations at a position influenced by genotype at other positions?

Effects of egg-passaging mutations

#### Documented phenotypic effects of egg mutations

	Documented egg mutation?	HA domain	Viral replication in eggs	Antigenicity
L194P		190-helix, antigenic site B	1	Δ
G186V		Antigenic site B	1	Neutral
T160K		Antigenic site B, glycosylation	<b>1</b>	Δ
T203I	sequenced.			
S219F/Y			1	<b>∆</b> / Neutral
D225G	in H1N1	220-loop	↑ (in H1N1)	Neutral (in H1N1)
A138S	sequenced.	130-loop, antigenic site A		
H156Q/R		Antigenic site B	↑ (H156Q)	<b>∆</b> (H156Q)

#### Phenotypic effects based on titers model

 Substitution model (Neher et al, 2016): ascribe titer drops to amino acid substitutions

#### Phenotypic effects based on titers model

 Substitution model (Neher et al, 2016): ascribe titer drops to amino acid substitutions

	Antigenic units (2-fold decrease in titer)		
	HI	FRA	
L194P	1.556	1.4434	
G186V	0.7317	0.2806	
T160K	0.2864	0.8269	
T203I	0.1125	None	
S219F	0.6432	None	
S219Y	0.2013	0.3543	

	Antigenic units (2-fold decrease in titer)		
	HI	FRA	
D225G	None	0.7157	
A138S	None	0.2315	
H156Q	None	None	
H156R	None	None	

#### Still to be done

- 1. Continuation of these analyses
  - a. Titers model interpretation
  - b. Larger n
  - c. Predict mutation based on background

#### 2. Potential additional analyses

- a. Synonymous mutations
- b. NA mutations
- c. H1N1 mutations